Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H31NO2S |
Molecular Weight | 349.531 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(OCCN1CCCCCC1)C(C2CCCCC2)C3=CSC=C3
InChI
InChIKey=MMNICIJVQJJHHF-UHFFFAOYSA-N
InChI=1S/C20H31NO2S/c22-20(23-14-13-21-11-6-1-2-7-12-21)19(18-10-15-24-16-18)17-8-4-3-5-9-17/h10,15-17,19H,1-9,11-14H2
Molecular Formula | C20H31NO2S |
Molecular Weight | 349.531 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Cetiedil is effective potassium channel blocker used as a peripheral vasodilator to treat patients with painful crises in sickle cell anemia and pain in the extremities caused by an arterial disease. Known pharmacological properties of the drug include vascular smooth muscle relaxation, inhibition of phosphodiesterase with the consequent increase in circulating cyclic AMP concentration, blockade of the effect of bradykinin and serotonin, analgesia, inhibition of platelet aggregation and the decrease of plasma and blood viscosity and plasma fibrinogen level. The antisickling effect of cetiedil is explained mainly in the light of the changes it induces in the activities of membrane-bound ATPases and the permeability properties of the erythrocyte membrane to cations and anions.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and structure-activity relationships of cetiedil analogues as blockers of the Ca(2+)-activated K+ permeability of erythrocytes. | 2001 Sep 27 |
|
An analysis of the mechanism by which cetiedil inhibits sickling. | 2002 Jan 18 |
|
Inhibition of the antigen-induced activation of RBL-2H3 cells by cetiedil and some of its analogues. | 2004 Jan 12 |
|
Inhibition of the antigen-induced activation of RBL-2H3 cells by charybdotoxin and cetiedil. | 2004 Jan 12 |
|
Pharmacology of the human red cell voltage-dependent cation channel; Part I. Activation by clotrimazole and analogues. | 2004 May-Jun |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:05:24 GMT 2023
by
admin
on
Fri Dec 15 17:05:24 GMT 2023
|
Record UNII |
621RT200TO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC04AX26
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
||
|
WHO-ATC |
C04AX26
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
14176-10-4
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
SUB07450MIG
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
621RT200TO
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
3171
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
66384
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
238-028-2
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
DB13753
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
580
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
C79584
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL419380
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
20609
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
m3289
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
CETIEDIL
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
DTXSID70864474
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
100000081512
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY | |||
|
C006955
Created by
admin on Fri Dec 15 17:05:24 GMT 2023 , Edited by admin on Fri Dec 15 17:05:24 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |